<DOC>
	<DOCNO>NCT00002038</DOCNO>
	<brief_summary>The primary purpose protocol provide fluconazole treatment individual patient require therapy serious life-threatening systemic fungal infection , fail conventional antifungal therapy unacceptable reaction conventional antifungal therapy , ineligible establish fluconazole clinical trial protocol .</brief_summary>
	<brief_title>Non-Comparative Study Fluconazole Patients With Serious Mycoses Who Can Be Treated With Conventional Antifungal Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : A patient exclude he/she previously unacceptable adverse effect due fluconazole . A patient exclude he/she previously unacceptable adverse effect due fluconazole . AMENDED : 900207 Open unapproved indication and/or age range . Original design : Patients clinically establish serious lifethreatening systemic fungal disease consider conventional fungal therapy acceptable alternative . Unacceptability conventional therapy define : Failure conventional therapy control eradicate infection appropriate trial ( ) generally accept regimen ( ) . Serious unacceptable untoward reaction ( ) conventional antifungal therapy . OR A major contraindication use conventional antifungal therapy . The patient must ineligible access establish fluconazole investigational protocol . The final judgment patient acceptability inclusion lie Pfizer Clinical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1996</verification_date>
	<keyword>Mycoses</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Fluconazole</keyword>
</DOC>